Danaher (DHR) Competitors

Danaher (NYSE:DHR) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

Does the media prefer DHR or RGEN?

In the previous week, Danaher had 28 more articles in the media than Repligen. MarketBeat recorded 44 mentions for Danaher and 16 mentions for Repligen. Danaher's average media sentiment score of 1.59 beat Repligen's score of 0.93 indicating that Danaher is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Danaher	41 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Repligen	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk & volatility, DHR or RGEN?

Danaher has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500. Comparatively, Repligen has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500.

Which has preferable earnings & valuation, DHR or RGEN?

Danaher has higher revenue and earnings than Repligen. Repligen is trading at a lower price-to-earnings ratio than Danaher, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Danaher	$23.88B	6.02	$3.90B	$4.70	42.70
Repligen	$634.44M	9.87	-$25.51M	-$0.25	-445.72

Do analysts recommend DHR or RGEN?

Danaher currently has a consensus target price of $247.61, indicating a potential upside of 23.37%. Repligen has a consensus target price of $169.45, indicating a potential upside of 52.07%. Given Repligen's higher possible upside, analysts clearly believe Repligen is more favorable than Danaher.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Danaher	0 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.85
Repligen	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Is DHR or RGEN more profitable?

Danaher has a net margin of 14.21% compared to Repligen's net margin of -2.05%. Danaher's return on equity of 10.70% beat Repligen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Danaher	14.21%	10.70%	6.85%
Repligen	-2.05%	4.65%	3.26%

Do institutionals & insiders have more ownership in DHR or RGEN?

79.1% of Danaher shares are owned by institutional investors. Comparatively, 97.6% of Repligen shares are owned by institutional investors. 11.1% of Danaher shares are owned by company insiders. Comparatively, 1.2% of Repligen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Danaher beats Repligen on 12 of the 16 factors compared between the two stocks.